Section Arrow
IMRN.NASDAQ
- Immuron Limited
(Financial Status)
Quotes are at least 15-min delayed:2026/04/09 05:22 EDT
Pre Market
Last
 0.8144
+0.0144 (+1.80%)
Bid
0.8144
Ask
0.8977
High 0.9004 
Low 0.7604 
Volume 18.89K 
Regular Hours (Closed)
Last
 0.8
+0.0067 (+0.84%)
Day High 
0.8192 
Prev. Close
0.7933 
1-M High
0.8943 
Volume 
32.79K 
Bid
0.8144
Ask
0.8977
Day Low
0.77 
Open
0.7707 
1-M Low
0.7 
Market Cap 
6.48M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.79 
20-SMA 0.78 
50-SMA 0.79 
52-W High 2.39 
52-W Low 0.6765 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.75/-0.50
Enterprise Value
6.55M
Balance Sheet
Book Value Per Share
1.10
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
7.29M
Operating Revenue Per Share
0.15
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
QNCXQuince Therapeutics0.1831+0.0201+12.33%-- 
Pre Market 0.1642 -0.0189 -10.32%
VRAXVirax Biolabs Group Limited0.15+0.01+7.14%-- 
Pre Market 0.142 -0.008 -5.33%
ELABPmgc Holdings Inc4.5+1.05+30.43%0PE
Pre Market 4.47 -0.03 -0.67%
CUECue Biopharma0.2738+0.0856+45.48%-- 
Pre Market 0.2299 -0.0439 -16.03%
GERNGeron Corp1.71-0.03-1.72%-- 
Pre Market 1.7 -0.01 -0.58%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.